| ²é¿´: 202 | »Ø¸´: 0 | |||
mcechinaгæ (³õÈëÎÄ̳)
|
[½»Á÷]
AntibacterialÒÖÖÆ¼Á(S)-TedizolidµÄÉúÎï»îÐÔ¡£
|
|
ÉúÎï»îÐÔ (S)-Tedizolid¾ßÓп¹¸ïÀ¼ÊÏÑôÐÔ¾úµÄ»îÐÔ¡£ Tedizolid is the active moiety of the prodrug tedizolid phosphate, with high potency against Gram-positive species. IC50 Value: N/A Target: Antibacterial The MIC(50) and MIC(90) of tedizolid against both methicillin-susceptible S. aureus (MSSA) and MRSA were 0.25 ¦Ìg/ml, compared with a MIC(50) of 1 ¦Ìg/ml and MIC(90) of 2 ¦Ìg/ml for linezolid. For coagulase-negative staphylococci (n = 7), viridans group streptococci (n = 15), and beta-hemolytic streptococci (n = 3), the MICs ranged from 0.03 to 0.25 ¦Ìg/ml for tedizolid and from 0.12 to 1 ¦Ìg/ml for linezolid. Torezolid (also known as TR-701 and now tedizolid) is an oxazolidinone drug in phase-II clinical trials for complicated skin and skin-structure infections (cSSSI), including those caused by Methicillin-resistant Staphylococcus aureus (MRSA). From Wikipedia |
» ²ÂÄãϲ»¶
µ°°×Öʼì²â£º¾«×¼·ÖÎö£¬½âËøÉúÎï·Ö×ÓµÄÃÜÂë
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑé֮СÊóʵÑ飺ÑϽ÷Éè¼Æ£¬½âÎöÉúÃü»úÖÆµÄÖØÒªÔØÌå
ÒѾÓÐ0È˻ظ´
»¯Ñ§¹¤³Ì¼°¹¤Òµ»¯Ñ§ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ277È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®ÖØ½ðÊô¼ì²â£º¾«×¼É¸²é£¬ÊØ»¤½¡¿µÓë»·¾³µÄ·ÀÏß
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®¡°ÍܲâÖØ½ðÊôÎÒ±³¹øÈýǧ¡±
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®¡°ÊóÌÓÈý´ÎÎÒ·¢ÈýƪSCI¡±
ÒѾÓÐ0È˻ظ´
ÄÉÃ×Á£¶È·ÖÎö
ÒѾÓÐ3È˻ظ´
ÁÖ¿ÆÔºÁÖ»¯ËùÕÐÊÕ²ÄÁÏÓ뻯¹¤×¨ÒµË¶Ê¿£¬×ø±êÄϾ©
ÒѾÓÐ0È˻ظ´
Áôѧ--²©Ê¿ÕÐÉú
ÒѾÓÐ15È˻ظ´
»¯Ñ§¹¤³Ì£¬±¾211£¬Çóµ÷¼Á£¬abÇø²»ÏÞ
ÒѾÓÐ4È˻ظ´













»Ø¸´´ËÂ¥